Insulet Corporation (PODD)
PODDNASDAQ-GSMedical/Dental Instruments
$148.06
-0.8100 (-0.54%) today
At the close, Nov 10, 4:00 PM ET. After hours $148.07 +0.01%
- Market cap
- $10.27bn
- P/E
- 22.4
- EPS, last 4 quarters
- $6.62
- Dividend yield
- –
- Day range
- $145.93 to $148.71
- 52-week range
- $126.40 to $354.88
- Average volume
- 1.63m
- Previous close
- $148.87
Analysts
13 coveringBuy6 buy, 7 hold, 0 sell
Targets a year out average $177.23, +19.7% from here
Earnings
next estimate $1.74Next report
Dec 2025
+4.7%
Mar 2026
+24.6%
Jun 2026
+15.3%
Sep 2026
+25.2%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $783.80m | $761.70m | $801.70m | $842.00m |
| Gross profit | $568.60m | $529.10m | $562.50m | $632.20m |
| Operating income | $146.30m | $122.10m | $129.70m | $189.70m |
| Net income | $101.60m | $91.10m | $95.00m | $141.00m |
Last four quarters: revenue $3.19bn, margin 13.4%, free cash flow $260.00m
News
8 latest- Is Insulet (PODD) a Solid Growth Stock? 3 Reasons to Think "Yes"Zacks · 3 hours ago
- What Insulet (PODD) Said on Its Q3 Earnings CallMarketBeat · 6 days ago
- Insulet (PODD) Q3 2026 Earnings Call TranscriptThe Motley Fool · 6 days ago
- Insulet Corporation Announces $1 billion Share Repurchase Program and Reports Third Quarter 2026 Financial ResultsFintel · 6 days ago
- Insulet Q3 Net Income Rises; Issues FY26 Outlook RTTNews · 6 days ago
- Insulet (PODD) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks · 6 days ago
- Insulet (PODD) Q3 Earnings and Revenues Surpass EstimatesZacks · 6 days ago
- Insulet (PODD) Reports Next Week: Wall Street Expects Earnings GrowthZacks · Oct 28, 2026
The company
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet's flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- insulet.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.